{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T10:24:39Z","timestamp":1766485479741,"version":"3.37.3"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.19090-30"],"award-info":[{"award-number":["320.6750.19090-30"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s00280-020-04151-8","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T13:03:51Z","timestamp":1601557431000},"page":"655-662","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Assessment of acute kidney injury related to small-molecule protein kinase inhibitors using the FDA adverse event reporting system"],"prefix":"10.1007","volume":"86","author":[{"given":"Qianqian","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8555-523X","authenticated-orcid":false,"given":"Bin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,1]]},"reference":[{"key":"4151_CR1","unstructured":"Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm. Accessed 22 Aug 2020"},{"key":"4151_CR2","doi-asserted-by":"publisher","first-page":"104609","DOI":"10.1016\/j.phrs.2019.104609","volume":"152","author":"R Roskoski Jr","year":"2020","unstructured":"Roskoski R Jr (2020) Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update. Pharmacol Res 152:104609. https:\/\/doi.org\/10.1016\/j.phrs.2019.104609","journal-title":"Pharmacol Res"},{"issue":"6","key":"4151_CR3","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/nrneph.2015.15","volume":"11","author":"C Porta","year":"2015","unstructured":"Porta C, Cosmai L, Gallieni M, Pedrazzoli P, Malberti F (2015) Renal effects of targeted anticancer therapies. Nat Rev Nephrol 11(6):354\u2013370. https:\/\/doi.org\/10.1038\/nrneph.2015.15","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"4151_CR4","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1097\/MCC.0000000000000355","volume":"22","author":"SL Goldstein","year":"2016","unstructured":"Goldstein SL (2016) Medication-induced acute kidney injury. Curr Opin Crit Care 22(6):542\u2013545. https:\/\/doi.org\/10.1097\/MCC.0000000000000355","journal-title":"Curr Opin Crit Care"},{"issue":"21","key":"4151_CR5","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1002\/cncr.29587","volume":"121","author":"M Yilmaz","year":"2015","unstructured":"Yilmaz M, Lahoti A, O'Brien S, Nogueras-Gonzalez GM, Burger J, Ferrajoli A, Borthakur G, Ravandi F, Pierce S, Jabbour E, Kantarjian H, Cortes JE (2015) Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer 121(21):3894\u20133904. https:\/\/doi.org\/10.1002\/cncr.29587","journal-title":"Cancer"},{"issue":"2","key":"4151_CR6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ygyno.2018.05.029","volume":"150","author":"JK Chan","year":"2018","unstructured":"Chan JK, Brady W, Monk BJ, Brown J, Shahin MS, Rose PG, Kim JH, Secord AA, Walker JL, Gershenson DM (2018) A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: an NRG Oncology\/Gynecologic Oncology Group Study (GOG-254). Gynecol Oncol 150(2):247\u2013252. https:\/\/doi.org\/10.1016\/j.ygyno.2018.05.029","journal-title":"Gynecol Oncol"},{"issue":"12","key":"4151_CR7","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/S1470-2045(17)30681-2","volume":"18","author":"P Ferolla","year":"2017","unstructured":"Ferolla P, Brizzi MP, Meyer T, Mansoor W, Mazieres J, Do Cao C, Lena H, Berruti A, Damiano V, Buikhuisen W, Gronbaek H, Lombard-Bohas C, Grohe C, Minotti V, Tiseo M, De Castro J, Reed N, Gislimberti G, Singh N, Stankovic M, Oberg K, Baudin E (2017) Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol 18(12):1652\u20131664. https:\/\/doi.org\/10.1016\/S1470-2045(17)30681-2","journal-title":"Lancet Oncol"},{"issue":"14","key":"4151_CR8","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1002\/cncr.28709","volume":"120","author":"V Launay-Vacher","year":"2014","unstructured":"Launay-Vacher V, Zimner-Rapuch S, Poulalhon N, Fraisse T, Garrigue V, Gosselin M, Amet S, Janus N, Deray G (2014) Acute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8 patients. Cancer 120(14):2158\u20132163. https:\/\/doi.org\/10.1002\/cncr.28709","journal-title":"Cancer"},{"key":"4151_CR9","doi-asserted-by":"publisher","first-page":"4327904","DOI":"10.1155\/2018\/4327904","volume":"2018","author":"U Syed","year":"2018","unstructured":"Syed U, Wahlberg KJ, Douce DR, Sprague JR (2018) Thrombotic thrombocytopenic purpura associated with pazopanib. Case Rep Hematol 2018:4327904. https:\/\/doi.org\/10.1155\/2018\/4327904","journal-title":"Case Rep Hematol"},{"issue":"1","key":"4151_CR10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s13256-018-1849-y","volume":"12","author":"P Ramachandran","year":"2018","unstructured":"Ramachandran P, Morcus R, Tahir M, Onukogu I, Spinowitz B, Wang JC (2018) Alectinib (Alecensa)-induced reversible grade IV nephrotoxicity: a case report and review of the literature. J Med Case Rep 12(1):303. https:\/\/doi.org\/10.1186\/s13256-018-1849-y","journal-title":"J Med Case Rep"},{"issue":"1","key":"4151_CR11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12882-018-1074-3","volume":"19","author":"Y Furuto","year":"2018","unstructured":"Furuto Y, Hashimoto H, Namikawa A, Outi H, Takahashi H, Horiuti H, Honda K, Shibuya Y (2018) Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report. BMC Nephrol 19(1):273. https:\/\/doi.org\/10.1186\/s12882-018-1074-3","journal-title":"BMC Nephrol"},{"issue":"9","key":"4151_CR12","doi-asserted-by":"publisher","first-page":"E223","DOI":"10.1002\/ajh.25546","volume":"94","author":"S Manohar","year":"2019","unstructured":"Manohar S, Bansal A, Wanchoo R, Sakhiya V, Lucia S, Jhaveri KD (2019) Ibrutinib induced acute tubular injury: a case series and review of the literature. Am J Hematol 94(9):E223\u2013E225. https:\/\/doi.org\/10.1002\/ajh.25546","journal-title":"Am J Hematol"},{"issue":"4","key":"4151_CR13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nrneph.2017.2","volume":"13","author":"LS Chawla","year":"2017","unstructured":"Chawla LS, Bellomo R, Bihorac A, Goldstein SL, Siew ED, Bagshaw SM, Bittleman D, Cruz D, Endre Z, Fitzgerald RL, Forni L, Kane-Gill SL, Hoste E, Koyner J, Liu KD, Macedo E, Mehta R, Murray P, Nadim M, Ostermann M, Palevsky PM, Pannu N, Rosner M, Wald R, Zarbock A, Ronco C, Kellum JA, Acute Disease Quality Initiative W (2017) Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol 13(4):241\u2013257. https:\/\/doi.org\/10.1038\/nrneph.2017.2","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"4151_CR14","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/phar.2152","volume":"38","author":"HK Welch","year":"2018","unstructured":"Welch HK, Kellum JA, Kane-Gill SL (2018) Drug-associated acute kidney injury identified in the United States food and drug administration adverse event reporting system database. Pharmacotherapy 38(8):785\u2013793. https:\/\/doi.org\/10.1002\/phar.2152","journal-title":"Pharmacotherapy"},{"key":"4151_CR15","unstructured":"Food and Drug Administration (2018) Data Mining at the Center for Drug Evaluation and Research. https:\/\/www.fda.gov\/science-research\/data-mining\/data-mining-center-drug-evaluation-and-research. Accessed 22 Aug 2020"},{"issue":"12","key":"4151_CR16","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1002\/pds.4672","volume":"27","author":"C Fukazawa","year":"2018","unstructured":"Fukazawa C, Hinomura Y, Kaneko M, Narukawa M (2018) Significance of data mining in routine signal detection: analysis based on the safety signals identified by the FDA. Pharmacoepidemiol Drug Saf 27(12):1402\u20131408. https:\/\/doi.org\/10.1002\/pds.4672","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"4151_CR17","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/clpt.2013.24","volume":"93","author":"R Harpaz","year":"2013","unstructured":"Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH (2013) Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther 93(6):539\u2013546. https:\/\/doi.org\/10.1038\/clpt.2013.24","journal-title":"Clin Pharmacol Ther"},{"key":"4151_CR18","unstructured":"MedDRA MSSO (2019) Introductory Guide for Standardised MedDRA Queries (SMQs) Version 21.0. https:\/\/www.meddra.org\/sites\/default\/files\/guidance\/file\/000356_smq_intguide_22_1.pdf. Accessed 22 Aug 2020"},{"key":"4151_CR19","unstructured":"Food and Drug Administration (2020) FDA Adverse Event Reporting System (FAERS) Quarterly Data Extract Files. https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html. Accessed 22 Aug 2020"},{"key":"4151_CR20","unstructured":"Kidney disease: improving global outcomes (KDIGO) Acute Kidney Injury Work Group (2012) KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2(1):1\u2013138. https:\/\/www.sciencedirect.com\/journal\/kidney-international-supplements\/vol\/2\/issue\/1. Accessed 22 Aug 2020"},{"key":"4151_CR21","unstructured":"Food and Drug Administration (2016) What is a serious adverse event? https:\/\/www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event. Accessed 22 Aug 2020"},{"key":"4151_CR22","unstructured":"Zink RC (2016) Disproportionality analysis and its application to spontaneously reported adverse events in pharmacovigilance. https:\/\/www.jmp.com\/content\/dam\/jmp\/documents\/en\/white-papers\/disproportionality-105686.pdf. Accessed 22 Aug 2020"},{"issue":"6","key":"4151_CR23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/BF03256733","volume":"22","author":"Y Chen","year":"2008","unstructured":"Chen Y, Guo JJ, Steinbuch M, Lin X, Buncher CR, Patel NC (2008) Comparison of sensitivity and timing of early signal detection of four frequently used signal detection methods. Pharmaceutical Medicine 22(6):359\u2013365","journal-title":"Pharmaceutical Medicine"},{"key":"4151_CR24","doi-asserted-by":"crossref","unstructured":"Poluzzi E, Raschi E, Piccinni C, Ponti FD (2012) Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA Adverse Event Reporting System (AERS). Data Mining Applications in Engineering and Medicine. https:\/\/api.intechopen.com\/chapter\/pdf-preview\/38579. Accessed 22 Aug 2020","DOI":"10.5772\/50095"},{"issue":"6","key":"4151_CR25","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369(6):507\u2013516. https:\/\/doi.org\/10.1056\/NEJMoa1306220","journal-title":"N Engl J Med"},{"issue":"2","key":"4151_CR26","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2174\/15748863113089990030","volume":"8","author":"IA Wahab","year":"2013","unstructured":"Wahab IA, Pratt NL, Kalisch LM, Roughead EE (2013) The detection of adverse events in randomized clinical trials: can we really say new medicines are safe? Curr Drug Saf 8(2):104\u2013113. https:\/\/doi.org\/10.2174\/15748863113089990030","journal-title":"Curr Drug Saf"},{"issue":"7537","key":"4151_CR27","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/bmj.38701.399942.63","volume":"332","author":"YK Loke","year":"2006","unstructured":"Loke YK, Price D, Derry S, Aronson JK (2006) Case reports of suspected adverse drug reactions\u2014systematic literature survey of follow-up. BMJ 332(7537):335\u2013339. https:\/\/doi.org\/10.1136\/bmj.38701.399942.63","journal-title":"BMJ"},{"issue":"3","key":"4151_CR28","doi-asserted-by":"publisher","first-page":"F740","DOI":"10.1152\/ajprenal.00049.2017","volume":"313","author":"R Boddu","year":"2017","unstructured":"Boddu R, Fan C, Rangarajan S, Sunil B, Bolisetty S, Curtis LM (2017) Unique sex- and age-dependent effects in protective pathways in acute kidney injury. Am J Physiol Renal Physiol 313(3):F740\u2013F755. https:\/\/doi.org\/10.1152\/ajprenal.00049.2017","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"4151_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12882-018-0937-y","volume":"19","author":"J Neugarten","year":"2018","unstructured":"Neugarten J, Golestaneh L, Kolhe NV (2018) Sex differences in acute kidney injury requiring dialysis. BMC Nephrol 19(1):131. https:\/\/doi.org\/10.1186\/s12882-018-0937-y","journal-title":"BMC Nephrol"},{"issue":"1","key":"4151_CR30","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1681\/ASN.2010090934","volume":"22","author":"S Anderson","year":"2011","unstructured":"Anderson S, Eldadah B, Halter JB, Hazzard WR, Himmelfarb J, Horne FM, Kimmel PL, Molitoris BA, Murthy M, O'Hare AM, Schmader KE, High KP (2011) Acute kidney injury in older adults. J Am Soc Nephrol 22(1):28\u201338. https:\/\/doi.org\/10.1681\/ASN.2010090934","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"4151_CR31","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ekir.2017.04.009","volume":"2","author":"J Cerda","year":"2017","unstructured":"Cerda J, Mohan S, Garcia-Garcia G, Jha V, Samavedam S, Gowrishankar S, Bagga A, Chakravarthi R, Mehta R (2017) Acute kidney injury recognition in low- and middle-income countries. Kidney Int Rep 2(4):530\u2013543. https:\/\/doi.org\/10.1016\/j.ekir.2017.04.009","journal-title":"Kidney Int Rep"},{"issue":"6","key":"4151_CR32","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1053\/j.ajkd.2015.12.018","volume":"67","author":"J Lunyera","year":"2016","unstructured":"Lunyera J, Kilonzo K, Lewington A, Yeates K, Finkelstein FO (2016) Acute kidney injury in low-resource settings: barriers to diagnosis, awareness, and treatment and strategies to overcome these barriers. Am J Kidney Dis 67(6):834\u2013840. https:\/\/doi.org\/10.1053\/j.ajkd.2015.12.018","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"4151_CR33","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41581-018-0052-0","volume":"14","author":"EAJ Hoste","year":"2018","unstructured":"Hoste EAJ, Kellum JA, Selby NM, Zarbock A, Palevsky PM, Bagshaw SM, Goldstein SL, Cerda J, Chawla LS (2018) Global epidemiology and outcomes of acute kidney injury. Nat Rev Nephrol 14(10):607\u2013625. https:\/\/doi.org\/10.1038\/s41581-018-0052-0","journal-title":"Nat Rev Nephrol"},{"issue":"24","key":"4151_CR34","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/MD.0000000000000207","volume":"93","author":"H Izzedine","year":"2014","unstructured":"Izzedine H, Escudier B, Lhomme C, Pautier P, Rouvier P, Gueutin V, Baumelou A, Derosa L, Bahleda R, Hollebecque A, Sahali D, Soria JC (2014) Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center. Medicine (Baltimore) 93(24):333\u2013339. https:\/\/doi.org\/10.1097\/MD.0000000000000207","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"4151_CR35","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/ndt\/gfn625","volume":"24","author":"SK Winn","year":"2009","unstructured":"Winn SK, Ellis S, Savage P, Sampson S, Marsh JE (2009) Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect? Nephrol Dial Transplant 24(2):673\u2013675. https:\/\/doi.org\/10.1093\/ndt\/gfn625","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"4151_CR36","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/j.1442-2042.2012.03039.x","volume":"19","author":"K Iwasaki","year":"2012","unstructured":"Iwasaki K, Obara W, Fujioka T (2012) Case of complete response to everolimus for metastatic renal cell carcinoma. Int J Urol 19(9):891\u2013892. https:\/\/doi.org\/10.1111\/j.1442-2042.2012.03039.x","journal-title":"Int J Urol"},{"issue":"1","key":"4151_CR37","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s13256-017-1384-2","volume":"11","author":"I Ismail","year":"2017","unstructured":"Ismail I, Nigam S, Parnham A, Srinivasa V (2017) Anti-glomerular basement membrane glomerulonephritis following nintedanib for idiopathic pulmonary fibrosis: a case report. J Med Case Rep 11(1):214. https:\/\/doi.org\/10.1186\/s13256-017-1384-2","journal-title":"J Med Case Rep"},{"issue":"6","key":"4151_CR38","first-page":"267","volume":"70","author":"ES den Deurwaarder","year":"2012","unstructured":"den Deurwaarder ES, Desar IM, Steenbergen EJ, Mulders PF, Wetzels JF, van Herpen CM (2012) Kidney injury during VEGF inhibitor therapy. Neth J Med 70(6):267\u2013271","journal-title":"Neth J Med"},{"issue":"3","key":"4151_CR39","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.bbapap.2009.12.001","volume":"1804","author":"RJ Dowling","year":"2010","unstructured":"Dowling RJ, Topisirovic I, Fonseca BD, Sonenberg N (2010) Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta 1804(3):433\u2013439. https:\/\/doi.org\/10.1016\/j.bbapap.2009.12.001","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"4151_CR40","doi-asserted-by":"publisher","first-page":"455","DOI":"10.4081\/oncol.2019.455","volume":"13","author":"RK Paluri","year":"2019","unstructured":"Paluri RK, Sonpavde G, Morgan C, Rojymon J, Mar AH, Gangaraju R (2019) Renal toxicity with mammalian target of rapamycin inhibitors: a meta-analysis of randomized clinical trials. Oncol Rev 13(2):455. https:\/\/doi.org\/10.4081\/oncol.2019.455","journal-title":"Oncol Rev"},{"key":"4151_CR41","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1186\/1471-2407-14-906","volume":"14","author":"SH Ha","year":"2014","unstructured":"Ha SH, Park JH, Jang HR, Huh W, Lim HY, Kim YG, Kim DJ, Oh HY, Lee JE (2014) Increased risk of everolimus-associated acute kidney injury in cancer patients with impaired kidney function. BMC Cancer 14:906. https:\/\/doi.org\/10.1186\/1471-2407-14-906","journal-title":"BMC Cancer"},{"issue":"9","key":"4151_CR42","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1093\/annonc\/mdt233","volume":"24","author":"H Izzedine","year":"2013","unstructured":"Izzedine H, Escudier B, Rouvier P, Gueutin V, Varga A, Bahleda R, Soria JC (2013) Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven. Ann Oncol 24(9):2421\u20132425. https:\/\/doi.org\/10.1093\/annonc\/mdt233","journal-title":"Ann Oncol"},{"issue":"5","key":"4151_CR43","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s00280-017-3300-2","volume":"79","author":"C Teuma","year":"2017","unstructured":"Teuma C, Pelletier S, Amini-Adl M, Perier-Muzet M, Maucort-Boulch D, Thomas L, Laville M, Fouque D, Dalle S (2017) Adjunction of a MEK inhibitor to Vemurafenib in the treatment of metastatic melanoma results in a 60% reduction of acute kidney injury. Cancer Chemother Pharmacol 79(5):1043\u20131049. https:\/\/doi.org\/10.1007\/s00280-017-3300-2","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"4151_CR44","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s40620-015-0226-9","volume":"28","author":"L Cosmai","year":"2015","unstructured":"Cosmai L, Gallieni M, Porta C (2015) Renal toxicity of anticancer agents targeting HER2 and EGFR. J Nephrol 28(6):647\u2013657. https:\/\/doi.org\/10.1007\/s40620-015-0226-9","journal-title":"J Nephrol"},{"issue":"2","key":"4151_CR45","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00280-016-3086-7","volume":"78","author":"C Teuma","year":"2016","unstructured":"Teuma C, Perier-Muzet M, Pelletier S, Nouvier M, Amini-Adl M, Dijoud F, Duru G, Thomas L, Fouque D, Laville M, Dalle S (2016) New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma. Cancer Chemother Pharmacol 78(2):419\u2013426. https:\/\/doi.org\/10.1007\/s00280-016-3086-7","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"4151_CR46","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.lungcan.2013.08.007","volume":"82","author":"L Gastaud","year":"2013","unstructured":"Gastaud L, Ambrosetti D, Otto J, Marquette CH, Coutts M, Hofman P, Esnault V, Favre G (2013) Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma. Lung Cancer 82(2):362\u2013364. https:\/\/doi.org\/10.1016\/j.lungcan.2013.08.007","journal-title":"Lung Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04151-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-020-04151-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04151-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T01:56:59Z","timestamp":1633053419000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-020-04151-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["4151"],"URL":"https:\/\/doi.org\/10.1007\/s00280-020-04151-8","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2020,10,1]]},"assertion":[{"value":"31 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was waived by the Institutional Review Board of Peking Union Medical College Hospital because this was an observational study based on the FAERS, which is a public anonymized database.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All data have been presented in the tables, figure and online resource. Other related information is available under request to the corresponding author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}